EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?

BACKGROUND: EGFR tyrosine kinase inhibitors (TKIs) have greatly improved the outcomes of EGFR mutation-positive adenocarcinomas of the lung. In contrast, the significance of EGFR mutation in metastatic squamous cell carcinoma (SCC) of the lung has been debated. METHODS: All patients with metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Amit, Zanwar, Saurabh, Noronha, Vanita, Patil, Vijay M, Chougule, Anuradha, Kumar, Rajiv, Janu, Amit, Mahajan, Abhishek, Kapoor, Akhil, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378442/
https://www.ncbi.nlm.nih.gov/pubmed/28405166
http://dx.doi.org/10.2147/OTT.S125397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378442/
https://www.ncbi.nlm.nih.gov/pubmed/28405166
http://dx.doi.org/10.2147/OTT.S125397

Ejemplares similares